<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cancer</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins </title>
      <description>
        <![CDATA[If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731634</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731634-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-compass.webp?t=1770672078" type="image/jpeg" medium="image" fileSize="512881">
        <media:title type="plain">China compass </media:title>
      </media:content>
    </item>
    <item>
      <title>‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios  </title>
      <description>
        <![CDATA[Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731632</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731632-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-handshake-with-coin-chart-background.webp?t=1704408549" type="image/jpeg" medium="image" fileSize="317806">
        <media:title type="plain">Deal handshake with coin, chart background</media:title>
      </media:content>
    </item>
    <item>
      <title>Simcere Zaiming Pharmaceutical discovers new MAPK inhibitors</title>
      <description>
        <![CDATA[Simcere Zaiming Pharmaceutical Co. Ltd. has divulged new mitogen-activated protein kinase (MAPK) inhibitors found to be potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731687</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731687-simcere-zaiming-pharmaceutical-discovers-new-mapk-inhibitors</link>
    </item>
    <item>
      <title>Avelos Therapeutics synthesizes new PARG inhibitors</title>
      <description>
        <![CDATA[Avelos Therapeutics Inc. has identified new poly(ADP-ribose) glycohydrolase (PARG) inhibitors that are potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731686</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731686-avelos-therapeutics-synthesizes-new-parg-inhibitors</link>
    </item>
    <item>
      <title>Hengrui Pharmaceutical divulges new VAV1 degradation inducers</title>
      <description>
        <![CDATA[Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have reported molecular glue degraders acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of cancer, inflammatory disorders and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731684</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731684-hengrui-pharmaceutical-divulges-new-vav1-degradation-inducers</link>
    </item>
    <item>
      <title>Sichuan Kelun-Biotech patents new anthracyclins</title>
      <description>
        <![CDATA[Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed new anthracyclins that are useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731683</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731683-sichuan-kelun-biotech-patents-new-anthracyclins</link>
    </item>
    <item>
      <title>Lipopolyplex-delivered, DISE-inducing small RNAs as broad-spectrum anticancer therapy</title>
      <description>
        <![CDATA[Previous work found that certain short RNAs can induce cell death in a RISC-dependent fashion by targeting several networks of survival genes simultaneously, therefore triggering multiple cell death pathways. This form of cell death was named death induced by survival gene elimination, or DISE, an effect that depends on a toxic 6-mer seed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731676</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731676-lipopolyplex-delivered-dise-inducing-small-rnas-as-broad-spectrum-anticancer-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Targeted-cancer-cell.webp?t=1741213881" type="image/jpeg" medium="image" fileSize="269059">
        <media:title type="plain">Targeted cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>AxS007 penetrates BBB for breast cancer brain metastases</title>
      <description>
        <![CDATA[About 90% of brain metastases are often limited therapeutically speaking due to the impermeable blood-brain barrier (BBB). Nanocarry Therapeutics Ltd. has presented AxS007, a novel insulin-mediated nanocarrier that delivers multiple copies of trastuzumab and pertuzumab across the BBB, using native insulin as a brain transporter and increasing brain exposure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731675</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731675-axs007-penetrates-bbb-for-breast-cancer-brain-metastases</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Blood-Brain-Barrier-Illustration.webp?t=1678203491" type="image/png" medium="image" fileSize="856287">
        <media:title type="plain">Illustration of brain in head highlighting the blood-brain barier.</media:title>
      </media:content>
    </item>
    <item>
      <title>Preclinical evaluation of a CAIX-targeted PET tracer</title>
      <description>
        <![CDATA[The University of Texas MD Anderson Cancer Center reported findings from studies of CBT-001-2334, a radionuclide peptide targeting carbonic anhydrase IX (CAIX/CA9) designed for diagnostic gallium labeling and downstream therapeutic isotope pairing. It features a DOTA chelator for use in theranostic applications through chelating either diagnostic or therapeutic radionuclides. Because it has limited expression in normal tissue, CAIX is an attractive target in clear cell renal cell carcinoma (ccRCC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731674</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731674-preclinical-evaluation-of-a-caix-targeted-pet-tracer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Open-blue-capsule-with-yellow-radioactive-symbol.webp?t=1776106225" type="image/jpeg" medium="image" fileSize="149663">
        <media:title type="plain">Open blue capsule with yellow radioactive symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Pfizer’s integrin β6 ADC advances intravesical therapy for NMIBC</title>
      <description>
        <![CDATA[Researchers from Pfizer reported preclinical efficacy of PF-08052667, an antibody-drug conjugate (ADC) targeting integrin β6 (ITGB6), in non-muscle-invasive bladder cancer (NMIBC) models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731672</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731672-pfizers-integrin-6-adc-advances-intravesical-therapy-for-nmibc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/ADC-antibody-drug-conjugate-green.webp?t=1706306980" type="image/jpeg" medium="image" fileSize="182154">
        <media:title type="plain">3D rendering of drug linked to antibody</media:title>
      </media:content>
    </item>
    <item>
      <title>Ona raises $86.6M series B for ADCs to treat advanced cancers</title>
      <description>
        <![CDATA[Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731620</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731620-ona-raises-866m-series-b-for-adcs-to-treat-advanced-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-dollar-sign.webp?t=1624487200" type="image/png" medium="image" fileSize="316216">
        <media:title type="plain">3D dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent submits NDA for CLDN18.2 ADC for gastric cancer</title>
      <description>
        <![CDATA[Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731617</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731617-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Gastric-cancer-illustration.webp?t=1610744617" type="image/png" medium="image" fileSize="551352">
        <media:title type="plain">Gastric cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Zynlonta Lotis position in DLBCL strains ADC shares</title>
      <description>
        <![CDATA[ADC Therapeutics SA blamed patients’ advanced age on the death imbalance in the phase III Lotis-5 confirmatory trial testing Zynlonta (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Whatever the reason, Wall Street wasn’t pleased and shares (NYSE:ADCT) closed June 4 at $1.32, down 57%, or $1.77.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731616</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731616-zynlonta-lotis-position-in-dlbcl-strains-adc-shares</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Diffuse-large-B-cell-lymphoma---isometric-view.webp?t=1780608328" type="image/jpeg" medium="image" fileSize="141240">
        <media:title type="plain">Diffuse large B-cell lymphoma - isometric view</media:title>
      </media:content>
    </item>
    <item>
      <title>Pfizer patents new PI3Kα mutant inhibitors</title>
      <description>
        <![CDATA[Pfizer Inc. has reported new biaryl acid compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) H1047R mutant inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731666</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731666-pfizer-patents-new-pi3k-mutant-inhibitors</link>
    </item>
    <item>
      <title>Incyte discloses new GTPase KRAS inhibitors</title>
      <description>
        <![CDATA[Incyte Corp. has synthesized new GTPase KRAS inhibitors potentially useful for the treatment of cancer, inflammatory and immunological disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731663</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731663-incyte-discloses-new-gtpase-kras-inhibitors</link>
    </item>
    <item>
      <title>SKL-35501 shows broad antitumor activity in solid tumors</title>
      <description>
        <![CDATA[Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic target. SKL-35501 is a novel 225Ac-labeled radiopharmaceutical developed by SK Biopharmaceuticals Co. Ltd. that targets NTSR1 for α-particle therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731657</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731657-skl-35501-shows-broad-antitumor-activity-in-solid-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Dividing-cancer-cell-target.webp?t=1764171254" type="image/jpeg" medium="image" fileSize="760640">
        <media:title type="plain">Dividing cancer cells in the cross hairs</media:title>
      </media:content>
    </item>
    <item>
      <title>Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC</title>
      <description>
        <![CDATA[At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data on ATNM-400 in models of non-small-cell lung cancer (NSCLC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731655</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731655-preclinical-results-support-actiniums-radioconjugate-atnm400-for-nsclc</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/radioactive-antibody.webp?t=1737734122" type="image/jpeg" medium="image" fileSize="126933">
        <media:title type="plain">Illustration of antibody carrying radioactive isotope</media:title>
      </media:content>
    </item>
    <item>
      <title>Sotio Biotech’s SOT-106 designated orphan drug for osteosarcoma</title>
      <description>
        <![CDATA[Sotio Biotech AS’s SOT-106 has been granted orphan drug designation by the FDA for the treatment of osteosarcoma. SOT-106 is a next-generation antibody-drug conjugate targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumor-associated stroma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731653</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731653-sotio-biotechs-sot-106-designated-orphan-drug-for-osteosarcoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/osteosarcoma-bone-cancer-knee-illustration.webp?t=1780586547" type="image/jpeg" medium="image" fileSize="560760">
        <media:title type="plain">Illustration of bone cancer in the knee</media:title>
      </media:content>
    </item>
    <item>
      <title>Uprising in pancreatic space more than Revolution</title>
      <description>
        <![CDATA[Oppenheimer analyst Jay Olson trumpeted “a new era” in pancreatic ductal adenocarcinoma (PDAC) after Revolution Medicines Inc.’s data splash with daraxonrasib at the American Society of Clinical Oncology meeting in Chicago – but he wasn’t talking about only that company. Combined with other recent updates in the space, the phase III data from Redwood City, Calif.-based Revolution is providing investors as well as patients with renewed hope in notoriously difficult-to-treat PDAC.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731542</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731542-uprising-in-pancreatic-space-more-than-revolution</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas-puzzle.webp?t=1780518809" type="image/jpeg" medium="image" fileSize="113959">
        <media:title type="plain">Pancreas puzzle with surgical tools</media:title>
      </media:content>
    </item>
    <item>
      <title>Mammogen raises $30M for blood-based breast cancer detection assay</title>
      <description>
        <![CDATA[Mammogen Inc. raised $30 million in equity financing in a series A round to support the clinical advancement and commercialization of its RNA-powered molecular diagnostics platform. The company’s lead product is Gentru-breast, a blood-based assay designed to detect molecular signatures associated with breast cancer from a simple blood draw. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731541</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731541-mammogen-raises-30m-for-blood-based-breast-cancer-detection-assay</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Cytomx, Regeneron expand bispecifics deal to potential $4B</title>
      <description>
        <![CDATA[Cytomx Therapeutics Inc. and Regeneron Pharmaceuticals Inc., which inked a bispecifics-focused collaboration worth up to $2 billion in 2022, agreed to broaden their efforts in an expanded deal that provides Cytomx with additional funding up front as it advances its promising colorectal cancer candidate, varsetatug masetecan (Varseta-M), and fills the gap left by the recently terminated agreement with Astellas Pharma Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731540</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731540-cytomx-regeneron-expand-bispecifics-deal-to-potential-4b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Digital-handshake.webp?t=1683126686" type="image/jpeg" medium="image" fileSize="453851">
        <media:title type="plain">Digital handshake </media:title>
      </media:content>
    </item>
    <item>
      <title>IMU’s $53M series A to advance high-definition immune profiling tech</title>
      <description>
        <![CDATA[IMU Biosciences Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731669</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731669-imus-53m-series-a-to-advance-high-definition-immune-profiling-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Pound-sign-on-tech-background.webp?t=1780434872" type="image/jpeg" medium="image" fileSize="224337">
        <media:title type="plain">Pound sign on tech background</media:title>
      </media:content>
    </item>
    <item>
      <title>Sichuan Kelun-Biotech prepares GSPT1-degrading PROTACs</title>
      <description>
        <![CDATA[Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has reported new proteolysis targeting chimera (PROTACs) compounds comprising a cereblon E3 ubiquitin ligase-binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731608</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731608-sichuan-kelun-biotech-prepares-gspt1-degrading-protacs</link>
    </item>
    <item>
      <title>FAPα inhibitors disclosed in Chomix Biotech patent</title>
      <description>
        <![CDATA[Chomix Biotech (Nanjing) Co. Ltd. has patented new irreversible fibroblast activation protein-α (FAPα) inhibitors potentially useful for the diagnosis or treatment of rheumatoid arthritis, atherosclerosis, cancer, myocardial infarction, kidney fibrosis, pulmonary and hepatic fibrosis, and among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731607</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731607-fap-inhibitors-disclosed-in-chomix-biotech-patent</link>
    </item>
    <item>
      <title>Synnovation Therapeutics reports new PARG inhibitors</title>
      <description>
        <![CDATA[Synnovation Therapeutics Inc. has identified new heterocyclic poly(ADP-ribose) glycohydrolase (PARG) inhibitors described as useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731606</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731606-synnovation-therapeutics-reports-new-parg-inhibitors</link>
    </item>
    <item>
      <title>CSPC’s SYS-6063 gains Chinese trial clearance for SLE</title>
      <description>
        <![CDATA[CSPC Pharmaceutical Group Ltd. has obtained clinical trial clearance from China’s National Medical Products Administration (NMPA) for SYS-6063, an mRNA-LNP-based dual-target CAR T-cell injection for the treatment of relapsed or refractory systemic lupus erythematosus (SLE).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731596</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731596-cspcs-sys-6063-gains-chinese-trial-clearance-for-sle</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Systemic-Lupus-Erythematosus.webp?t=1684937966" type="image/jpeg" medium="image" fileSize="100180">
        <media:title type="plain">Concept art for systemic lupus erythematosus R&amp;D</media:title>
      </media:content>
    </item>
    <item>
      <title>ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal</title>
      <description>
        <![CDATA[Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731644</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731644-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Antibodies-attacking-cancer-cell.webp?t=1621365766" type="image/png" medium="image" fileSize="566115">
        <media:title type="plain">Antibodies attacking cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>IMU’s $53M series A to advance high-definition immune profiling tech</title>
      <description>
        <![CDATA[IMU Biosciences Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731528</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731528-imus-53m-series-a-to-advance-high-definition-immune-profiling-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Pound-sign-on-tech-background.webp?t=1780434872" type="image/jpeg" medium="image" fileSize="224337">
        <media:title type="plain">Pound sign on tech background</media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Celcuity’s positive phase III gets no love from investors</title>
      <description>
        <![CDATA[Minneapolis-based Celcuity Inc. was like the Rolling Stones at the 2026 American Society of Clinical Oncology annual meeting. The company reported positive phase III data for its pan-PI3K/mTORC1/2 inhibitor gedatolisib, but Celcuity (NASDAQ:CELC) couldn’t get any satisfaction from investors who sent shares down 25.7%, or $31.54, to $91.42 on June 2, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731527</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731527-asco-2026-celcuitys-positive-phase-iii-gets-no-love-from-investors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Dec-2020/Science-breast-cancer-cell-12-9.webp?t=1607542510" type="image/png" medium="image" fileSize="570840">
        <media:title type="plain">Breast cancer cell</media:title>
        <media:description type="plain">Breast cancer cell. Credit: Bruce Wetzel and Harry Schaefer, NCI</media:description>
      </media:content>
    </item>
    <item>
      <title>Cancer specter looming, Abtect effect in UC wallops Abivax</title>
      <description>
        <![CDATA[Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up in phase III top-line data from the Abtect maintenance trial with obefazimod. Paris-based Abivax SA’s oral, first-in-class miRNA-124 enhancer performed well in adults with moderately to severely active ulcerative colitis (UC), but shares of (NASDAQ:ABVX) closed June 2 at $72.50, down 44%, or $57.19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731525</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731525-cancer-specter-looming-abtect-effect-in-uc-wallops-abivax</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Stomach-pain.webp?t=1745258577" type="image/jpeg" medium="image" fileSize="208753">
        <media:title type="plain">Person holding stomach in pain </media:title>
      </media:content>
    </item>
  </channel>
</rss>
